Allen Frances, MD, a leading critic of DSM-5 and best-selling author, shares his take on where the new manual goes wrong.

The new DSM-5 will change the way clinicians diagnose substance use disorders (SUD) and could have far-reaching consequences for patients seeking treatment and clinicians and organizations offering that treatment.

Addiction has been around seemingly forever. However, how we have conceptualized it, has changed considerably over time.

Learn the motivation and reasoning behind the substance use disorders section of DSM-5 in this interview with chair of the substance use disorders workgroup, Charles P O’Brien, MD, PhD

In advance of the official release of DSM-5 this May, the field trial data has been reported in three papers in the American Journal of Psychiatry.

Sometime in 2013, we’ll presumably be forced to shell out a hundred bucks or so for the fifth edition of DSM. While we do not have the space to review every potential change here, we will cover those of most clinical importance.